Associated tags: Depression, M1, Idiopathic pulmonary fibrosis, Disease, LPA1, Therapy, Multiple sclerosis, Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, IPF, Patient, Inflammation, Pharmaceutical industry
Locations: SAN DIEGO, CA, US, SAN FRANCISCO, NEW YORK, NI
Montgomery Street,
Goldman Sachs,
Vesey Street,
Telephone,
Inflammation,
SAN,
Sale,
Attention,
Security (finance),
Prospectus,
Morgan Stanley,
Suite,
Therapy,
Varick Street,
Equity capital markets,
RBC Capital Markets All of the shares are being offered by Contineum.
Key Points:
- All of the shares are being offered by Contineum.
- The gross proceeds to Contineum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Contineum, are expected to be $110.0 million.
- In addition, Contineum has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions.
- Goldman Sachs & Co. LLC, Morgan Stanley, Stifel, and RBC Capital Markets are acting as joint book-running managers for the offering.
Retrieved on:
Wednesday, December 13, 2023
Health,
Neurology,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
IPF,
Multiple sclerosis,
M1,
Patient,
Therapy,
Inflammation,
Pharmaceutical industry,
LPA1 Pipeline Therapeutics, Inc. (the Company) announced today that it has changed its name to Contineum Therapeutics, Inc. (Contineum).
Key Points:
- Pipeline Therapeutics, Inc. (the Company) announced today that it has changed its name to Contineum Therapeutics, Inc. (Contineum).
- The Company chose Contineum (pronounced "Con-tin-E-um") to represent its continuous dedication to the pursuit of scientific discovery and cutting-edge solutions designed to benefit patients.
- Contineum is focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need.
- "Our goal is to create precision small molecules that can alter the course of clinical impairment in neurology, inflammation and immunology diseases.
